Viking Therapeutics Inc said on Tuesday its experimental drug met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease, sending its shares about 6% higher in early trade.

The drugmaker, which will begin a mid-stage trial for the drug in mid-2023, is entering the race to develop an obesity treatment, which has contenders including Altimmune, Novo Nordisk, and Eli Lilly.